Pirfenidone in Idiopathic Pulmonary Fibrosis “RECAP-itulating Safety into the Real World”

Publisher： Karger

E-ISSN： 1423-0356|94|5|405-407

ISSN： 0025-7931

Source： Respiration, Vol.94, Iss.5, 2017-09, pp. : 405-407

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP)

By  

Respiration, Vol. 94, Iss. 5, 2017-09 ,pp. : 408-415

Karger

Access to resources Recommend Favorite

Pirfenidone in Idiopathic Pulmonary Fibrosis: Real-Life Experience from a German Tertiary Referral Center for Interstitial Lung Diseases

By  

Respiration, Vol. 88, Iss. 3, 2014-08 ,pp. : 199-207

Karger

Access to resources Recommend Favorite

Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report

By  

Respiration, Vol. 91, Iss. 4, 2016-04 ,pp. : 327-332

Karger

Access to resources Recommend Favorite

Pirfenidone and inhaled NAC for IPF

By  

RESPIROLOGY (ELECTRONIC), Vol. 20, Iss. 3, 2015-04 ,pp. : 445-452

John Wiley & Sons Inc

Access to resources Recommend Favorite

Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone

By  

Respiration, Vol. 93, Iss. 6, 2017-04 ,pp. : 415-423

Karger

Access to resources Recommend Favorite